Aptuit
AMRI buys two Aptuit facilities
January 13, 2015Manufacturing and Production AMRI, Aptuit, cedarburg, glasgow, oso
Contract research and manufacturing firm AMRI has acquired two businesses from pharmaceutical services company Aptuit in a $60 million deal. …
Aptuit hires chief executive from ICON
December 3, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Aptuit, ICON, goldman
Drug development services firm Aptuit has named Dr Jonathan Goldman as its chief executive, completing the company’s senior management leadership …
MHRA wins data scam case
March 13, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Aptuit, MHRA, data
An ex-employee of research organisation Aptuit has been found guilty of changing pre-clinical trial data as part of a bid to …
Contract research news in brief
February 11, 2013Research and Development Antabio, Aptuit, Argenta, Cross Country Healthcare, ICON, PPD, Quintiles, Verum.de
Icon offers $52m for CCH’s clinical services division, plus updates from PPD, Aptuit, Argenta, Quintiles and Verum.de.
Catalent to buy Aptuit and claim number two spot in clinical supply
August 30, 2011Manufacturing and Production Aptuit, Catalent, manufacturing and production news
Catalent Pharma Solutions has agreed to purchase the clinical trial supply business of Aptuit in a $410 million deal which …
Scottish First Minister seeks talks with Aptuit over plant closures
December 21, 2010Manufacturing and Production Aptuit, Scotland, manufacturing facilities, pharma manufacturing
US contract manufacturing and drug development company Aptuit says it may shut down two facilities in Lothian, Scotland, because demand …
Aptuit deal saves GSK’s R&D unit in Verona
July 5, 2010Manufacturing and Production, Research and Development Aptuit, GlaxoSmithKline, Italy
GlaxoSmithKline has sold off its medicines research facility in Verona, Italy, to contract research and manufacturing service group Aptuit in …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
